Arexvy

Arexvy (RSVPreF3 OA) is a recombinant subunit vaccine developed by GSK for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). The vaccine contains a recombinant RSV fusion (F) glycoprotein stabilized in its prefusion conformation (RSVPreF3), which is the primary target for neutralizing antibodies. It is formulated with GSK's proprietary AS01E adjuvant system, which consists of the plant-derived saponin QS-21 and the toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPL) in a liposomal formulation. This combination induces a robust immune response, including high levels of neutralizing antibodies and antigen-specific CD4+ T-cell responses against both RSV-A and RSV-B subtypes. Arexvy was the first RSV vaccine to receive FDA approval, granted in May 2023 for adults aged 60 years and older.

Brand names

Arexvy

Other names

RSVPreF3RSVPreF-3RSVPreF 3Respiratory Syncytial Virus Vaccine, Adjuvanted